A comprehensive view of Non-Vaccine Biologics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Merck to acquire the University at Buffalo startup Abceutics for up to US$280.0M in a bid to enhance its antibody-drug conjugate pipeline; Abceutics is developing technology aimed at reducing the impact of therapies on healthy cells
Published: April 08, 2024 by FierceBiotech
FDA approves J&J’s CARVYKTI to treat patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy; an estimated 35,000 cases of the disease projected to be diagnosed this year in US
Published: April 06, 2024 by Janssen Pharmaceutical Companies
Becker's Hospital Review Underscores Industry Shifts with Vaccine Updates, Strikes, Legal Battles, Financial Challenges, Work-Life Reforms, Cyber Responses, and Pricing Scrutiny
Published: March 07, 2024 by Industry Intelligence Inc.
Regeneron announces formation of Regeneron Cell Medicines with the acquisition of 2seventy bio's full development and commercialization rights for novel immune cell therapies, along with discovery and clinical manufacturing capabilities
Published: January 30, 2024 by GlobeNewswire
Monash University, Moderna create the Monash-Moderna Quantitative Pharmacology Accelerator, a five-year program to drive mRNA medicine advancements, including therapeutics and vaccines; Moderna invests $3.0M in the Australia-based partnership
Published: August 16, 2023 by Targeted News Service

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count